Clarithromycin-resistant genotypes and eradication of Helicobacter pylori

Vincenzo De Francesco, Marcella Margiotta, Angelo Zullo, Cesare Hassan, Laura Troiani, Osvaldo Burattini, Francesca Stella, Alfredo Di Leo, Francesco Russo, Stefania Marangi, Rosa Monno, Vincenzo Stoppino, Sergio Morini, Carmine Panella, Enzo Ierardi

Research output: Contribution to journalArticle

Abstract

Background: Three point mutations (A2143G, A2142G, and A2142C) have been involved in Helicobacter pylori clarithromycin resistance. Objective: To compare the eradication rates among the different point mutations and the efficacy of triple therapy and a sequential regimen according to genotypic resistance. Design: Post hoc subgroup study from a multicenter, randomized trial. Setting: Two hospitals in central and southern Italy between January and December 2001. Patients: 156 patients with H. pylori infection. Measurements: Real-time polymerase chain reaction for assessing clarithromycin resistance; histology, rapid urease test, and 13C-urea breath test at entry and after 4 to 6 weeks. Intervention: 7-day triple therapy (20 mg of rabeprazole, 500 mg of clarithromycin, and 1 g of amoxicillin) in 75 patients or a 10-day sequential regimen (20 mg of rabeprazole plus 1 g of amoxicillin for 5 days and 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days) in 81 patients. All drugs were given twice daily. Results: Helicobacter pylori infection was eradicated in 11 of 23 patients (48%) with the A2143G mutation and in 14 of 15 patients (93%) with either A2142G or A2142C strains (difference, 45 percentage points [95% CI, 15 to 65 percentage points]; P = 0.004). The sequential regimen achieved a higher cure rate than triple therapy in A2143G mutate strains (difference, 49 percentage points [CI, 8 to 72 percentage points]; P = 0.024). Limitations: The post hoc substudy design may require further confirmation. Other limitations are the accessibility to the tool and the cost of investigations (€70 per patient). Conclusions: The A2143G mutation seemed to be associated with a very low eradication rate. The sequential regimen achieved a higher cure rate than standard therapy even in patients with these strains.

Original languageEnglish
Pages (from-to)94-100
Number of pages7
JournalAnnals of Internal Medicine
Volume144
Issue number2
Publication statusPublished - Jan 17 2006

Fingerprint

Clarithromycin
Helicobacter pylori
Genotype
Rabeprazole
Amoxicillin
Helicobacter Infections
Point Mutation
Tinidazole
Mutation
Breath Tests
Urease
Therapeutics
Italy
Multicenter Studies
Urea
Real-Time Polymerase Chain Reaction
Histology
Costs and Cost Analysis
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

De Francesco, V., Margiotta, M., Zullo, A., Hassan, C., Troiani, L., Burattini, O., ... Ierardi, E. (2006). Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Annals of Internal Medicine, 144(2), 94-100.

Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. / De Francesco, Vincenzo; Margiotta, Marcella; Zullo, Angelo; Hassan, Cesare; Troiani, Laura; Burattini, Osvaldo; Stella, Francesca; Di Leo, Alfredo; Russo, Francesco; Marangi, Stefania; Monno, Rosa; Stoppino, Vincenzo; Morini, Sergio; Panella, Carmine; Ierardi, Enzo.

In: Annals of Internal Medicine, Vol. 144, No. 2, 17.01.2006, p. 94-100.

Research output: Contribution to journalArticle

De Francesco, V, Margiotta, M, Zullo, A, Hassan, C, Troiani, L, Burattini, O, Stella, F, Di Leo, A, Russo, F, Marangi, S, Monno, R, Stoppino, V, Morini, S, Panella, C & Ierardi, E 2006, 'Clarithromycin-resistant genotypes and eradication of Helicobacter pylori', Annals of Internal Medicine, vol. 144, no. 2, pp. 94-100.
De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Annals of Internal Medicine. 2006 Jan 17;144(2):94-100.
De Francesco, Vincenzo ; Margiotta, Marcella ; Zullo, Angelo ; Hassan, Cesare ; Troiani, Laura ; Burattini, Osvaldo ; Stella, Francesca ; Di Leo, Alfredo ; Russo, Francesco ; Marangi, Stefania ; Monno, Rosa ; Stoppino, Vincenzo ; Morini, Sergio ; Panella, Carmine ; Ierardi, Enzo. / Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. In: Annals of Internal Medicine. 2006 ; Vol. 144, No. 2. pp. 94-100.
@article{d560b92eba3047d9a5da825edd1ff6b8,
title = "Clarithromycin-resistant genotypes and eradication of Helicobacter pylori",
abstract = "Background: Three point mutations (A2143G, A2142G, and A2142C) have been involved in Helicobacter pylori clarithromycin resistance. Objective: To compare the eradication rates among the different point mutations and the efficacy of triple therapy and a sequential regimen according to genotypic resistance. Design: Post hoc subgroup study from a multicenter, randomized trial. Setting: Two hospitals in central and southern Italy between January and December 2001. Patients: 156 patients with H. pylori infection. Measurements: Real-time polymerase chain reaction for assessing clarithromycin resistance; histology, rapid urease test, and 13C-urea breath test at entry and after 4 to 6 weeks. Intervention: 7-day triple therapy (20 mg of rabeprazole, 500 mg of clarithromycin, and 1 g of amoxicillin) in 75 patients or a 10-day sequential regimen (20 mg of rabeprazole plus 1 g of amoxicillin for 5 days and 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days) in 81 patients. All drugs were given twice daily. Results: Helicobacter pylori infection was eradicated in 11 of 23 patients (48{\%}) with the A2143G mutation and in 14 of 15 patients (93{\%}) with either A2142G or A2142C strains (difference, 45 percentage points [95{\%} CI, 15 to 65 percentage points]; P = 0.004). The sequential regimen achieved a higher cure rate than triple therapy in A2143G mutate strains (difference, 49 percentage points [CI, 8 to 72 percentage points]; P = 0.024). Limitations: The post hoc substudy design may require further confirmation. Other limitations are the accessibility to the tool and the cost of investigations (€70 per patient). Conclusions: The A2143G mutation seemed to be associated with a very low eradication rate. The sequential regimen achieved a higher cure rate than standard therapy even in patients with these strains.",
author = "{De Francesco}, Vincenzo and Marcella Margiotta and Angelo Zullo and Cesare Hassan and Laura Troiani and Osvaldo Burattini and Francesca Stella and {Di Leo}, Alfredo and Francesco Russo and Stefania Marangi and Rosa Monno and Vincenzo Stoppino and Sergio Morini and Carmine Panella and Enzo Ierardi",
year = "2006",
month = "1",
day = "17",
language = "English",
volume = "144",
pages = "94--100",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "2",

}

TY - JOUR

T1 - Clarithromycin-resistant genotypes and eradication of Helicobacter pylori

AU - De Francesco, Vincenzo

AU - Margiotta, Marcella

AU - Zullo, Angelo

AU - Hassan, Cesare

AU - Troiani, Laura

AU - Burattini, Osvaldo

AU - Stella, Francesca

AU - Di Leo, Alfredo

AU - Russo, Francesco

AU - Marangi, Stefania

AU - Monno, Rosa

AU - Stoppino, Vincenzo

AU - Morini, Sergio

AU - Panella, Carmine

AU - Ierardi, Enzo

PY - 2006/1/17

Y1 - 2006/1/17

N2 - Background: Three point mutations (A2143G, A2142G, and A2142C) have been involved in Helicobacter pylori clarithromycin resistance. Objective: To compare the eradication rates among the different point mutations and the efficacy of triple therapy and a sequential regimen according to genotypic resistance. Design: Post hoc subgroup study from a multicenter, randomized trial. Setting: Two hospitals in central and southern Italy between January and December 2001. Patients: 156 patients with H. pylori infection. Measurements: Real-time polymerase chain reaction for assessing clarithromycin resistance; histology, rapid urease test, and 13C-urea breath test at entry and after 4 to 6 weeks. Intervention: 7-day triple therapy (20 mg of rabeprazole, 500 mg of clarithromycin, and 1 g of amoxicillin) in 75 patients or a 10-day sequential regimen (20 mg of rabeprazole plus 1 g of amoxicillin for 5 days and 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days) in 81 patients. All drugs were given twice daily. Results: Helicobacter pylori infection was eradicated in 11 of 23 patients (48%) with the A2143G mutation and in 14 of 15 patients (93%) with either A2142G or A2142C strains (difference, 45 percentage points [95% CI, 15 to 65 percentage points]; P = 0.004). The sequential regimen achieved a higher cure rate than triple therapy in A2143G mutate strains (difference, 49 percentage points [CI, 8 to 72 percentage points]; P = 0.024). Limitations: The post hoc substudy design may require further confirmation. Other limitations are the accessibility to the tool and the cost of investigations (€70 per patient). Conclusions: The A2143G mutation seemed to be associated with a very low eradication rate. The sequential regimen achieved a higher cure rate than standard therapy even in patients with these strains.

AB - Background: Three point mutations (A2143G, A2142G, and A2142C) have been involved in Helicobacter pylori clarithromycin resistance. Objective: To compare the eradication rates among the different point mutations and the efficacy of triple therapy and a sequential regimen according to genotypic resistance. Design: Post hoc subgroup study from a multicenter, randomized trial. Setting: Two hospitals in central and southern Italy between January and December 2001. Patients: 156 patients with H. pylori infection. Measurements: Real-time polymerase chain reaction for assessing clarithromycin resistance; histology, rapid urease test, and 13C-urea breath test at entry and after 4 to 6 weeks. Intervention: 7-day triple therapy (20 mg of rabeprazole, 500 mg of clarithromycin, and 1 g of amoxicillin) in 75 patients or a 10-day sequential regimen (20 mg of rabeprazole plus 1 g of amoxicillin for 5 days and 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days) in 81 patients. All drugs were given twice daily. Results: Helicobacter pylori infection was eradicated in 11 of 23 patients (48%) with the A2143G mutation and in 14 of 15 patients (93%) with either A2142G or A2142C strains (difference, 45 percentage points [95% CI, 15 to 65 percentage points]; P = 0.004). The sequential regimen achieved a higher cure rate than triple therapy in A2143G mutate strains (difference, 49 percentage points [CI, 8 to 72 percentage points]; P = 0.024). Limitations: The post hoc substudy design may require further confirmation. Other limitations are the accessibility to the tool and the cost of investigations (€70 per patient). Conclusions: The A2143G mutation seemed to be associated with a very low eradication rate. The sequential regimen achieved a higher cure rate than standard therapy even in patients with these strains.

UR - http://www.scopus.com/inward/record.url?scp=33644798246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644798246&partnerID=8YFLogxK

M3 - Article

C2 - 16418408

AN - SCOPUS:33644798246

VL - 144

SP - 94

EP - 100

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 2

ER -